Melbourne, Australia - 3 June 2014: The Chief Executive Officer of Australian biopharmaceutical company. Immuron Limited (ASX: IMC) will present at a prestigious Australian biotechnology investment conference in Hong Kong on 5 June 2014.
Chief Executive Office Mr Amos Meltzer’s presentation will outline:
• The ongoing strengthening market presence for the Company’s flagship product Travelan® and the near term opportunities which includes commercialisation of Travelan® in certain Asian countries;
• An overview of the Company’s main value proposition – The Phase II NASH clinical trial due to commence later in 2014;
• The Phase IIB ASH trial – also due to commence later in 2014 and funded by the National Institute of Health; and
• Information around the Company’s unique platform technology, as illustrated by a C. difficile development program due to follow the NASH programme into the clinical phase;
Ahead of the conference Mr Meltzer commented “I am pleased to be presenting at the Asia Biotech Invest Conference as it is a very relevant opportunity for Immuron, particularly given its current pursuit of the commercialisation of Travelan® in Asia. Furthermore given that the treatment of NASH is a large unmet medical need in many Asian countries the Immuron’s upcoming phase II clinical trial is of enormous relevance and interest. This conference is a great opportunity for Immuron to raise awareness on Travelan® and to reach out to Asian-based investors”
This conference is Asia’s largest biotech investment event which brings together hundreds of biotech investors, big pharma representatives and industry analysts. It is regarded a premium opportunity for biotech companies from the Asia-Pacific region to present an investment case and attract funding.
Immuron Chairman, Mr Roger Aston described Immuron’s presentation at the 2014 Asia Biotech Invest Conference as “a wonderful opportunity for investors outside of Australia to receive and appreciate the Company’s existing product offering and its increasing market potential in Asia, together with the excitement surrounding the upcoming commencement of the ASH/NASH clinical trial”.
Contact
Amos Meltzer, Chief Executive Officer Peter Vaughan, Company Secretary
+61 437 587 680
+61 3 9824 5254
Investor Relations
Amanda Loh, Buchan Consulting
+6139866 4722
Websites: www.immuron.com and www.travelan.com
About Immuron
Immuron is a biopharmaceutical company focused on oral immunotherapy treatments using dairy-derived antibody products for humans. Immuron’s technology platform products all have a very high safety profile. The company’s current products and product candidates address infectious diseases of the gastrointestinal tract as well as chronic diseases. Immuron has an on-market product, Travelan®, for preventing travellers’ diarrhoea. Immuron also has a phase 2 clinical product candidate for the treatment of inflamed fatty liver disease, known as Non-Alcoholic Steatohepatitis or NASH. Immuron’s main scientific alliances are with Hadassah Medical Center (Israel) and Monash University (Australia).
Help employers find you! Check out all the jobs and post your resume.
